Page 1

BLIS Technologies 11 February 2021 Business performance and year end guidance update Blis Technologies Limited's ( BLT : NZX ) programme of investment in new markets and product pipeline initiatives is the cornerstone growth driver for the business ' future success . Third quarter activity supporting this strategy has seen several key projects reach finalisation with business partners , leading to the announcement of product roll out programmes . " Last month we launched the BLIS PROBIOTICS ™ store on Alibaba's Tmall Global marketplace tmall.com . As China's largest cross - border marketplace , Tmall Global is the premier channel through which overseas brands and retailers can directly reach Chinese consumers , build brand awareness and gain valuable consumer insights . The store is the ideal market entry for introducing BLIS PROBIOTICS ™ to the Chinese market ” said Blis Chief Executive , Brian Watson . " Along with this we've received Health Canada approvals for our full product range . These approvals were delayed due to COVID - 19 but will enable Blis to launch the range in Canada in the 4th quarter of this financial year " . Both of these significant market developments occurred late in this financial year so will have limited impact on the FY21 financial results but they are both expected to be important contributors to sales in future years . " Our new product development pipeline offers several exciting new probiotic based product lines . We are in the late stages of launch planning for our skincare range with the first release to market expected early in the new financial year . The product a " Live probiotic hydration serum " powered by our unique patented strain BLIS Q24 , will target the lucrative cosmetic market and has gone through extensive market research in the US and New Zealand , receiving very favourable customer feedback in both markets " . The product will initially be launched in NZ direct to consumers supported by a high profile multichannel campaign . Over time we intend to expand launch activity to the US and our China Tmall global site . Skincare is seen as having the potential to be a significant future revenue driver for Blis and we will look to bring to market other unique products to expand our presence in this thriving category . Year to date performance Trading revenue for the 9 months ending 31 December 2020 increased 10 % to $ 8.2m , compared with the previous year . EBITDA increased 12 % to $ 1.5m . Results for the period Third quarter Year to date ended 31 Dec FY21 FY20 Trading revenue $ 2.4m $ 2.3m Change + $ 0.1m FY21 $ 8.2m FY20 $ 7.5m Change + $ 0.7m + 6 % + 10 % EBITDA $ 0.2m $ 0.3m - $ 0.1m $ 1.5m $ 1.3m + $ 0.2m .38 % + 12 %